Koninklijke Philips (PHIA) Show & Tell 2024 summary
Event summary combining transcript, slides, and related documents.
Show & Tell 2024 summary
20 Jan, 2026Opening and agenda
The event began with a welcome, outlining a day focused on innovation, value creation, and customer engagement, including presentations, Q&A, and hands-on demos at the Customer Experience Center.
Attendees were provided with digital access to the agenda and presenter bios via QR codes.
Strategic vision and market context
The company is focused on delivering impactful, sustainable healthcare innovations, addressing both sick care and self-care.
The addressable market is expected to reach €90 billion by 2025, driven by aging populations, chronic diseases, and staff shortages, with technology positioned to bridge care gaps.
Emphasis is placed on expanding access, efficiency, and sustainability in healthcare, leveraging digital and AI advancements.
Key strategic themes
Focus on advancing precise and predictive imaging, personal health, and connected care to address growing healthcare demand and productivity pressures.
Emphasis on sustainable, people- and patient-centric innovation, with over 9% of sales invested in R&D and half of sales from recent product launches.
Execution priorities include embedding patient safety and quality, optimizing supply chains, and simplifying operating models.
ESG leadership integrated into strategy, maintaining carbon neutrality and focusing on health impact for underserved populations.
Culture shift towards impact with care, accountability, and HealthTech expertise, with significant executive renewal.
Latest events from Koninklijke Philips
- Targeting mid-single-digit sales growth and mid-teens margin by 2028 through innovation and execution.PHIA
CMD 202610 Feb 2026 - Strong 2025 growth and margin gains set up for higher sales and profitability in 2026.PHIA
Q4 202510 Feb 2026 - All AGM proposals passed, with focus on profitability, ESG, and resilience amid global risks.PHIA
AGM 20253 Feb 2026 - Q2 saw 2% sales growth, 9% order intake rise, margin gains, and major Respironics settlements.PHIA
Q2 20242 Feb 2026 - Strong margin gains offset flat sales and China weakness, with robust operational performance.PHIA
Q3 202418 Jan 2026 - 2024 saw margin gains, strong cash flow, and finalized US Respironics settlements despite China declines.PHIA
Q4 20248 Jan 2026 - Sales fell 2% but order intake and net income improved; margin guidance cut on tariffs.PHIA
Q1 202524 Nov 2025 - Margin up 130 bps to 12.4% on 1% sales growth and strong order intake; guidance raised.PHIA
Q2 20255 Nov 2025 - Q3 2025 saw 8% order growth, 3% sales growth, and margin expansion, with strong cash flow.PHIA
Q3 20254 Nov 2025